Clinical TrialMay 28, 2026, 09:07 AM
MiNK Therapeutics Doses First Patient in Phase 2 for Acute Lung Injury
AI Summary
MiNK Therapeutics announced that the first patient has been dosed in its randomized Phase 2 clinical trial (C-1300-02) evaluating agenT-797 for severe acute lung injury and critical illness. This milestone marks a rapid transition from trial activation to active treatment for a first-in-class immune therapy where no approved mortality-reducing therapies exist. The trial, conducted in collaboration with UNBROKEN Ukraine, is designed to assess clinically meaningful ICU outcomes, with preliminary data expected in the second half of 2026.
Key Highlights
- MiNK Therapeutics dosed the first patient in its randomized Phase 2 clinical trial (C-1300-02) for agenT-797.
- The trial evaluates agenT-797 with standard of care vs placebo with standard of care for acute lung injury.
- The study targets severe acute lung injury and critical illness meeting Global ARDS criteria.
- Preliminary data from the trial are expected in the second half of 2026.
- Acute lung injury and ARDS have mortality exceeding 40-50%, with no approved mortality-reducing therapies.
- The trial was initiated at First Lviv Territorial Medical Union in Lviv, Ukraine, with US site expansion underway.
- The study assesses clinically meaningful ICU outcomes, including survival and ventilator-free days.
Price Impact
More from INKT